Rubicon Research Q4 FY26: The Outsourcing Trap and a 86x P/E Waiting for Pithampur

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Revenue hit ₹514 Cr in Q4, up 44% year-on-year. Profit jumped 112%, but net profit landed at ₹77 Cr—a thin 15% of sales. The stock sits at P/E 86.4x, a three-tier lift from its own 5-year average of 60.8x. Margins held at 23%, yet gross profit was pressured by outsourced manufacturing (more on that torture below). Cash piled up to ₹346 Cr, half the company’s market cap. The Pithampur facility is still waiting for its FDA inspection date; management says Q1 CY27 ramps are “on track”—which in pharma-speak means “pending inspection.”

Working capital bloated to 104 days from 92 last year, a warning sign wrapped in inventory labeled “fuel for growth.”

2. Introduction

Rubicon Research went public in October 2025 at ₹ 733 per share and listed at ₹ 773. Nine months later, the stock trades 68% higher. The IPO raised ₹1,378 Cr; management deployed it into three buckets: debt repayment, the ₹ 176 Cr Arinna Lifesciences acquisition (April 2026, 85% stake), and Pithampur capex.

For context, the company has been around since 1999, operating three USFDA-approved plants across India and serving the US generic market (99.5% of revenue). It has 66 commercialized products and 81 FDA approvals, focused on oral solids, liquids, and nasal sprays. In January 2026, AdvaGen Pharma (Rubicon’s US arm) received a ₹ 419 Cr tax demand for FY 2021-22; management flagged an appeal is planned.

3. Business Model: WTF Do They Even Do?

Rubicon manufactures generic formulations in India and sells them into the US market through its own distribution subsidiary, AdvaGen Pharma, and wholesalers. The portfolio spans CNS drugs (27% of Q1 FY26 revenue), analgesics (24%), and cardiovascular (19%)—no single product carried more than 14% of sales.

The business model is a classic Indian pharma arbitrage: develop drugs in-house (R&D spend ₹194 Cr in FY26, 11% of sales), manufacture at scale across three plants, and funnel into a highly regulated, high-margin US market where supply is tight and switching is expensive.

Specialty drugs (fewer competitors at launch) contributed ₹ 200+ Cr gross margin in FY26—about 21% of the gross profit—a magnet for pharma investors hunting for pricing power. The company filed 24 products “under review” with the FDA as of the latest concall and approved 12 in FY26, so the pipeline velocity is real. Top 5 products sit at 39% of Q4 sales; top 10 at 57%, which management celebrated as “no concentration risk” (a tone-deaf framing: half your revenue riding on ten products is not resilience).

Dosage form split: oral solids 85.5%, liquids 10%, nasal 2%. All three categories see price stability “due to portfolio mix,” though this line will age poorly if tariff whims shift.

4. Financials Overview

Figures are consolidated, in ₹ crore.

FY26 annual: Revenue ₹1,754 Cr (+37% YoY), PAT ₹247 Cr (+84% YoY), EPS ₹14.98.

Concall context (Jun 2026): Management credited Q4 strength to broad-based demand (“not driven by a single product or two”) and reaffirmed EBITDA margin guidance at 22–23%, which they reiterated includes ESOP costs, Arinna integration costs, Pithampur pre-ramp costs, raw material and logistics inflation. The margin hold is the story: revenue is +67% EBITDA YoY, but gross margin compressed due to outsourced manufacturing. Management acknowledged they ramped outsourced volume to “avoid losing customers and product sales”—a euphemism for capacity crunch. They expect “at least a couple more quarters” of outsourcing reliance before internalization kicks back in.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently pays 86.4x earnings here versus a peer median of 31.99x. The gap reflects investor pricing for a near-term ramp and the specialty drug portfolio upside, though it sits above the company’s own 5-year historical range.

Return on equity stands at 27%, a 1,600bp improvement from the 5-year 16.5% average. ROCE is 28.4%, a credible capital-allocation track record. However, the margin of error shrinks: Pithampur requires FDA inspection clearance, Arinna must integrate profitably by FY28, and gross margin pressure is real near-term. The market appears to be pricing in a successful Pithampur ramp (raising EBITDA by ₹ 100+ Cr annually once full) and sustained specialty-drug margin bleed-through.

6. What’s Cooking

Pithampur facility: Acquired June 2025 for ₹ 149 Cr from Alkem. FDA site qualification complete. Products filed. FDA inspection pending. Management targets Q1 CY27 ramp-up; capacity utilization expected to reach “decent levels” within 12–18 months post-inspection. This is